ENTRADA THERAPEUTICS, INC. (TRDA) Operating Margin
- Operating margin · 12 months: Value -3767.07%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -3767.07% | Operating income / revenue. Period ending 2026-06-30. $-176.53M ÷ $4.69M × 100 ≈ -3767.07% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -176.53M USD | Operating Income (Loss) |
| Revenue | 4.69M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 140.74M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-176.53M | $4.69M | (m) | $140.74M | (m) | -3767.07% |
| 2026-03-31 | $-178.41M | $5.74M | (m) | $143.25M | (m) | -3109.29% |
| 2025-12-31 | $-157.90M | $25.42M | (m) | $142.27M | (m) | -621.13% |
| 2025-09-30 | $-121.56M | $61.52M | (m) | $141.72M | (m) | -197.59% |
| 2025-06-30 | $-96.16M | $79.48M | (m) | $134.61M | (m) | -121.00% |
| 2025-03-31 | $4.11M | $172.22M | (m) | $128.77M | (m) | 2.39% |
| 2024-12-31 | $47.01M | $210.78M | (m) | $125.31M | (m) | 22.30% |
| 2024-09-30 | $57.78M | $215.23M | (m) | $120.19M | (m) | 26.85% |
| 2024-06-30 | $93.45M | $239.40M | (m) | $111.13M | (m) | 39.04% |
| 2024-03-31 | $23.73M | $162.87M | (m) | $105.39M | (m) | 14.57% |
| 2023-12-31 | $-3.16M | $129.01M | (m) | $99.88M | (m) | -2.45% |
| 2023-09-30 | $-33.65M | (m) | (m) | $87.28M | (m) | (m) |
| 2023-06-30 | $-73.59M | (m) | (m) | $84.05M | (m) | (m) |
| 2023-03-31 | $-80.88M | (m) | (m) | $73.99M | (m) | (m) |
| 2022-12-31 | $-97.25M | (m) | (m) | $66.61M | (m) | (m) |
| 2022-09-30 | $-90.13M | (m) | (m) | $63.29M | (m) | (m) |
| 2022-06-30 | $-78.56M | (m) | (m) | $54.84M | (m) | (m) |
| 2022-03-31 | $-64.89M | (m) | (m) | $45.42M | (m) | (m) |
| 2021-12-31 | $-51.13M | (m) | (m) | $35.93M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-26.67M | (m) | (m) | $21.10M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |